

In the Claims

1-25 (canceled).

26 (currently amended). A method of ~~preventing or~~ treating a peripheral neurological disease comprising the administration of a composition comprising clusterin, ~~an isoform, mutein, a clusterin fusion protein or a PEGylated clusterin fused protein, functional derivative, active fraction, circularly permuted derivative, or salt thereof, or an agonist of clusterin activity~~ to an individual having peripheral neurological disease in an amount effective to treat said peripheral neurological disease, wherein said clusterin is selected from the group consisting of:

- (a) a clusterin polypeptide comprising SEQ ID NO: 1;
- (b) a clusterin polypeptide comprising amino acids 23 to 449 of SEQ ID NO: 1;
- (c) a clusterin polypeptide comprising amino acids 35 to 449 of SEQ ID NO: 1;
- (d) a clusterin polypeptide comprising amino acids 23 to 227 of SEQ ID NO: 1;
- (e) a clusterin polypeptide comprising amino acids 35 to 227 of SEQ ID NO: 1; and
- (f) a clusterin polypeptide comprising amino acids 228 to 449 of SEQ ID NO: 1.

27 (previously presented). The method according to claim 26, wherein the peripheral neurological disease is selected from the group consisting of traumatic nerve injury of the peripheral nervous system (PNS), demyelinating diseases of the PNS, peripheral neuropathies and peripheral neurodegenerative diseases.

28 (withdrawn). The method according to claim 26, wherein the peripheral neurological disease is caused by a congenital metabolic disorder.

29 (withdrawn). The method according to claim 27, wherein the peripheral neurological disease is a peripheral neuropathy.

30 (withdrawn). The method according to claim 29, wherein the peripheral neuropathy is diabetic neuropathy.

31 (withdrawn). The method according to claim 29, wherein the peripheral neuropathy is chemotherapy-induced neuropathy.

32 (canceled).

33 (currently amended). The method according to ~~claim 32~~claim 26, wherein the composition comprises PEGylated clusterin and said clusterin is selected from the group consisting of:

- (a) a clusterin polypeptide comprising SEQ ID NO: 1;
- (b) a clusterin polypeptide comprising amino acids 23 to 449 of SEQ ID NO: 1;
- (c) a clusterin polypeptide comprising amino acids 35 to 449 of SEQ ID NO: 1;
- (d) a clusterin polypeptide comprising amino acids 23 to 227 of SEQ ID NO: 1;
- (e) a clusterin polypeptide comprising amino acids 35 to 227 of SEQ ID NO: 1; and
- (f) a clusterin polypeptide comprising amino acids 228 to 449 of SEQ ID NO: 1
functional derivative comprises a PEG moiety.

34 (currently amended). The method according to ~~claim 34~~claim 26, wherein said composition comprises a clusterin fusion protein that comprises an immunoglobulin (Ig) constant region fused to a clusterin polypeptide selected from the group consisting of:

- (a) a clusterin polypeptide comprising SEQ ID NO: 1;
- (b) a clusterin polypeptide comprising amino acids 23 to 449 of SEQ ID NO: 1;
- (c) a clusterin polypeptide comprising amino acids 35 to 449 of SEQ ID NO: 1;
- (d) a clusterin polypeptide comprising amino acids 23 to 227 of SEQ ID NO: 1;
- (e) a clusterin polypeptide comprising amino acids 35 to 227 of SEQ ID NO: 1; and
- (f) a clusterin polypeptide comprising amino acids 228 to 449 of SEQ ID NO: 1
the fused protein comprises an immunoglobulin (Ig) fusion.

35 (previously presented). The method according to claim 26, wherein the composition further comprises heparin.

36 (previously presented). The method according to claim 26, wherein said composition is simultancously, sequentially, or separately administered with a composition comprising heparin.

37 (currently amended). The method according to claim 26, wherein the composition further comprises an interferon, osteopontin, or both ~~interferon~~interferon and osteopontin, for simultaneous, sequential, or separate-use administration.

38 (previously presented). The method according to claim 37, wherein the interferon is interferon- β .

39 (currently amended). The method according to claim 26, wherein the clusterin is ~~used~~administered in an amount of about 0.001 to 100 mg/kg of body weight, or about 1 to 10 mg/kg of body weight, or about 5 mg/kg of body weight.

40-43 (canceled).

44 (new). The method according to claim 26, wherein said clusterin polypeptide comprises SEQ ID NO: 1.

45 (new). The method according to claim 26, wherein said clusterin polypeptide comprises amino acids 23 to 449 of SEQ ID NO: 1.

46 (new). The method according to claim 26, wherein said clusterin polypeptide comprises amino acids 35 to 449 of SEQ ID NO: 1.

47 (new). The method according to claim 26, wherein said clusterin polypeptide comprises amino acids 23 to 227 of SEQ ID NO: 1.

48 (new). The method according to claim 26, wherein said clusterin polypeptide comprises amino acids 35 to 227 of SEQ ID NO: 1.

49 (new). The method according to claim 26, wherein said clusterin polypeptide comprises amino acids 228 to 449 of SEQ ID NO: 1.

50 (new). The method according to claim 33, wherein said PEGylated clusterin polypeptide comprises SEQ ID NO: 1.

51 (new). The method according to claim 33, wherein said PEGylated clusterin polypeptide comprises amino acids 23 to 449 of SEQ ID NO: 1.

52 (new). The method according to claim 33, wherein said PEGylated clusterin polypeptide comprises amino acids 35 to 449 of SEQ ID NO: 1.

53 (new). The method according to claim 33, wherein said PEGylated clusterin polypeptide comprises amino acids 23 to 227 of SEQ ID NO: 1.

54 (new). The method according to claim 33, wherein said PEGylated clusterin polypeptide comprises amino acids 35 to 227 of SEQ ID NO: 1.

55 (new). The method according to claim 33, wherein said PEGylated clusterin polypeptide comprises amino acids 228 to 449 of SEQ ID NO: 1.

56 (new). The method according to claim 34, wherein said clusterin fusion protein comprises an immunoglobulin (Ig) constant region fused to a clusterin polypeptide that comprises SEQ ID NO: 1.

57 (new). The method according to claim 34, wherein said clusterin fusion protein comprises an immunoglobulin (Ig) constant region fused to a clusterin polypeptide that comprises amino acids 23 to 449 of SEQ ID NO: 1.

58 (new). The method according to claim 34, wherein said clusterin fusion protein comprises an immunoglobulin (Ig) constant region fused to a clusterin polypeptide that comprises amino acids 35 to 449 of SEQ ID NO: 1.

59 (new). The method according to claim 34, wherein said clusterin fusion protein comprises an immunoglobulin (Ig) constant region fused to a clusterin polypeptide that comprises amino acids 23 to 227 of SEQ ID NO: 1.

60 (new). The method according to claim 34, wherein said clusterin fusion protein comprises an immunoglobulin (Ig) constant region fused to a clusterin polypeptide that comprises amino acids 35 to 227 of SEQ ID NO: 1.

61 (new). The method according to claim 34, wherein said clusterin fusion protein comprises an immunoglobulin (Ig) constant region fused to a clusterin polypeptide that comprises amino acids 228 to 449 of SEQ ID NO: 1.